title: Sodium hyaluronate eye drops treatment for superficial corneal abrasion caused by mechanical damage: a randomized clinical trial in the People's Republic of China.
abstract: OBJECTIVE
  To evaluate the effectiveness and safety of 0.3% sodium hyaluronate (HA) compared to recombinant bovine basic fibroblast growth factor (rb-bFGF) for the treatment of corneal epithelial abrasion caused by mechanical damage in Chinese patients.
  
  
  METHODS
  Thirty patients were randomly assigned to the HA or rb-bFGF treatment group. The HA group was treated with 0.3% HA and 0.5% levofloxacin, and the rb-bFGF group was treated with topical rb-bFGF and 0.5% levofloxacin. The primary endpoint was the clinical effectiveness rates at day 3. Secondary endpoints were the dimensions of the wound area and the percentage of wound closure.
  
  
  RESULTS
  After 3 days of treatment, the clinical effectiveness rates of the HA group and the rb-bFGF group were 86.67% (13/15) and 93.33% (14/15), respectively. The dimensions of the wound area were reduced from 9.83±8.50 to 0.02±0.06 mm(2) for the HA group at day 7, and from 10.58±9.94 to 0.02±0.07 mm(2) for the rb-bFGF group. At day 3, the wound closure was almost complete in both groups; 94.73% in the HA group compared to 95.77% in the rb-bFGF group (P>0.05).
  
  
  CONCLUSIONS
  Topical 0.3% HA provided a promising treatment for superficial corneal abrasion caused by mechanical damage in a manner similar to rb-bFGF.
authors: Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai, People's Republic of China.
authors: Tong
authors: T
authors: Lin
authors: Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai, People's Republic of China.
authors: Lan
authors: L
authors: Gong
mesh_terms: D060433:Administration, Ophthalmic; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002681:China; D065306:Corneal Injuries / Q000175:diagnosis / Q000188:drug therapy*; D019573:Epithelium, Corneal / Q000187:drug effects* / Q000293:injuries / Q000473:pathology; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D064704:Levofloxacin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011994:Recombinant Proteins / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000900:Anti-Bacterial Agents; D009883:Ophthalmic Solutions; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; D064704:Levofloxacin; D006820:Hyaluronic Acid
keywords: bovine basic fibroblast growth factor; sodium hyaluronate; superficial corneal abrasion